The New England journal of medicine, 2019-03, Vol.380 (11), p.1022-1032
2019
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
- Ist Teil von
- The New England journal of medicine, 2019-03, Vol.380 (11), p.1022-1032
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2019
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- Short-term studies indicate that bempedoic acid, an ATP citrate lyase inhibitor, reduces LDL cholesterol levels. In a 1-year trial, bempedoic acid added to maximally tolerated statin therapy did not lead to a higher incidence of adverse events than placebo and led to significantly lower LDL cholesterol levels.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1803917Titel-ID: cdi_proquest_journals_2213860717
- Format
- –
- Schlagworte
- Acids, Aged, Antilipemic agents, Apolipoproteins B - blood, Arteriosclerosis, ATP Citrate (pro-S)-Lyase - antagonists & inhibitors, ATP citrate lyase, C-Reactive Protein - analysis, Cancer, Cardiovascular disease, Cardiovascular diseases, Cholesterol, Cholesterol - blood, Cholesterol, LDL, Cholesterol, LDL - blood, Control, Dicarboxylic Acids - adverse effects, Dicarboxylic Acids - therapeutic use, Dosage and administration, Drug therapy, Drug Therapy, Combination, Enzymes, Evidence-based medicine, Fatty Acids - adverse effects, Fatty Acids - therapeutic use, Female, Gout, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use, Hypercholesterolemia, Hypercholesterolemia - blood, Hypercholesterolemia - drug therapy, Hypoglycemic Agents - adverse effects, Hypoglycemic Agents - therapeutic use, Lipids, Low density lipoprotein, Male, Middle Aged, Patients, Peptide Fragments - blood, Safety, Safety and security measures, Statins, Treatment Outcome, Tumors